Gallium-68 Labeling of the Cyclin-Dependent Kinase 4/6 Inhibitors as Positron Emission Tomography Radiotracers for Tumor Imaging
Open Access
- 18 November 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (47) , 32253-32261
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2020YFA0909003)
- Science and Technology Commission of Shanghai Municipality (19ZR1411300, 20YF1408500)
- Shanghai Municipal Health Commission (202040269)
- Science and Technology Development Fund of Shanghai Pudong New Area (PKJ2020-Y54)
This publication has 32 references indexed in Scilit:
- CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment FailureCurrent Breast Cancer Reports, 2017
- Gallium-68 in Medical ImagingCurrent Radiopharmaceuticals, 2016
- Palbociclib and Letrozole in Advanced Breast CancerNew England Journal of Medicine, 2016
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerNew England Journal of Medicine, 2016
- Drugging DNA repairScience, 2016
- Feasibility and availability of 68Ga-labelled peptidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitorsEuropean Journal of Medicinal Chemistry, 2010
- Positive feedback of G1 cyclins ensures coherent cell cycle entryNature, 2008
- PET versus SPECT: strengths, limitations and challengesNuclear Medicine Communications, 2008